7:16 am NewLink Genetics’ independent review committee recommends study continuation without modification after completion of first interim analysis of IMPRESS Phase 3 pancreatic cancer trial with algenpantucel-L
View todays social media effects on NLNK
View the latest stocks trending across Twitter. Click to view dashboard
See who NewLink is hiring next, click here to view
